Healthtech startup Vaxinano stands out with an innovative approach to vaccination by offering vaccines administered nasally. This strategic choice provides a new response to public health challenges, simplifying administration while maximizing treatment efficacy. Nasal administration, bypassing traditional injection methods, allows for rapid and targeted vaccine diffusion—a crucial asset for tackling complex infectious diseases.
More than a practical alternative, this delivery method opens new possibilities in preventing zoonotic diseases and pandemics. With its Stellar-NP platform, based on innovative nanoparticles, Vaxinano offers a solution for controlling challenging pathogens such as certain viruses, bacteria, and parasites. The absence of adjuvants in these vaccines enhances their safety and stability, two essential qualities for large-scale deployment.
Vaxinano’s technology has already shown its potential, providing both preventive and therapeutic solutions. Whether for treating leishmaniasis, toxoplasmosis, or colibacillosis, its vaccines deliver long-lasting immunity against diseases that pose a risk to both animals and humans. As climate change and new pandemics emerge, these technological advances take on even greater significance.
A €6 million funding round to accelerate market entry
In October 2024, Vaxinano raised €6 million in a funding round led by TCD Capital, Captech Santé, Nord France Amorçage, and Wiseed, with support from BPI France. This funding will strengthen the clinical development capacity of the Stellar-NP platform and prepare for commercialization stages. “This fundraising marks an important step in reaching our goal: bringing innovative vaccine solutions to market that meet global health challenges,” said Jonathan Stauber, CEO of Vaxinano.
